All Stories

  1. Development of a Kidney Transplant‐Specific DOOR for Urinary Tract Infections Assessing the Impact of Carbapenem Resistance

    Article • Transplant Infectious Disease, February 2026, Wiley

    Dr Toshimitsu Hamasaki

  2. A patient-centric paradigm and tool for clinical research: the DOOR is open

    Article • Antimicrobial Agents and Chemotherapy, November 2025, ASM Journals

    Dr Toshimitsu Hamasaki

  3. Efficacy and Safety of 5-Aminolevulinic Acid Hydrochloride Combined with Sodium Ferrous Citrate in Pediatric Patients with Leigh Syndrome and Central Nervous System Disorders: An Initial Exploratory Trial with a Double-Blind Placebo-Controlled Period, ...

    Article • Life, July 2025, MDPI AG

    Dr Toshimitsu Hamasaki

  4. Statistics in Biopharmaceutical Research Best Papers Award 2025

    Article • Statistics in Biopharmaceutical Research, June 2025, Taylor & Francis

    Dr Toshimitsu Hamasaki

  5. Inside the Mind of the DMC: A Review of Principles and Issues with Case Studies

    Article • Therapeutic Innovation & Regulatory Science, December 2024, Springer Science + Business Media

    Dr Toshimitsu Hamasaki

  6. Data Monitoring Committee Reports: Telling the Data’s Story

    Article • Therapeutic Innovation & Regulatory Science, December 2024, Springer Science + Business Media

    Dr Toshimitsu Hamasaki

  7. Longitudinal Benefit:risk Analysis through the Desirability of Outcome Ranking (DOOR) with Application to ACTT-1 Trial

    Article • Statistics in Biopharmaceutical Research, December 2024, Taylor & Francis

    Dr Toshimitsu Hamasaki

  8. Exploration of a Potential DOOR Endpoint for Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia Using Six Registrational Trials for Antibacterial Drugs

    Article • Clinical Infectious Diseases, March 2024, Oxford University Press (OUP)

    Dr Toshimitsu Hamasaki

  9. Priorities and Progress in Gram-negative Bacterial Infection Research by the Antibacterial Resistance Leadership Group

    Article • Clinical Infectious Diseases, October 2023, Oxford University Press (OUP)

    Dr Toshimitsu Hamasaki

  10. Priorities and Progress in Gram-positive Bacterial Infection Research by the Antibacterial Resistance Leadership Group: A Narrative Review

    Article • Clinical Infectious Diseases, October 2023, Oxford University Press (OUP)

    Dr Toshimitsu Hamasaki

  11. The Future Ain’t What It Used to Be…Out With the Old…In With the Better: Antibacterial Resistance Leadership Group Innovations

    Article • Clinical Infectious Diseases, October 2023, Oxford University Press (OUP)

    Dr Toshimitsu Hamasaki

  12. Under the Hood: The Scientific Leadership, Clinical Operations, Statistical and Data Management, and Laboratory Centers of the Antibacterial Resistance Leadership Group

    Article • Clinical Infectious Diseases, October 2023, Oxford University Press (OUP)

    Dr Toshimitsu Hamasaki

  13. Moving Beyond Mortality: Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia

    Article • Clinical Infectious Diseases, September 2023, Oxford University Press (OUP)

    Dr Toshimitsu Hamasaki

  14. Exploration of a Potential Desirability of Outcome Ranking Endpoint for Complicated Intra-Abdominal Infections Using 9 Registrational Trials for Antibacterial Drugs

    Article • Clinical Infectious Diseases, April 2023, Oxford University Press (OUP)

    Dr Toshimitsu Hamasaki

  15. Statistics in Biopharmaceutical Research Best Papers Award 2023

    Article • Statistics in Biopharmaceutical Research, April 2023, Taylor & Francis

    Dr Toshimitsu Hamasaki

  16. Editor’s Note: Special Section on Estimands, Design and Analysis of Clinical Trials with Time-to-Event Outcomes

    Article • Statistics in Biopharmaceutical Research, April 2023, Taylor & Francis

    Dr Toshimitsu Hamasaki

  17. Efficacy and safety of azithromycin versus placebo to treat lower respiratory tract infections associated with low procalcitonin: a randomised, placebo-controlled, double-blind, non-inferiority trial

    Article • The Lancet Infectious Diseases, April 2023, Elsevier

    Dr Toshimitsu Hamasaki

  18. Generalized fiducial inference for the restricted mean survival time

    Article • Statistical Methods in Medical Research, March 2023, SAGE Publications

    Dr Toshimitsu Hamasaki

  19. Editor’s Note: Special Section on a Collection of Articles on Opportunities and Challenges in Utilizing Real-World Data for Clinical Trials and Medical Product Development

    Article • Statistics in Biopharmaceutical Research, January 2023, Taylor & Francis

    Dr Toshimitsu Hamasaki

  20. Safety and microbiological activity of phage therapy in persons with cystic fibrosis colonized with Pseudomonas aeruginosa: study protocol for a phase 1b/2, multicenter, randomized, double-blind, placebo-controlled trial

    Article • Trials, December 2022, Springer Science + Business Media

    Dr Toshimitsu Hamasaki

  21. Weighing evidence: robustness vs quantity

    Article • JNCI Journal of the National Cancer Institute, September 2022, Oxford University Press (OUP)

    Dr Toshimitsu Hamasaki

  22. Improving Traditional Registrational Trial End Points: Development and Application of a Desirability of Outcome Ranking End Point for Complicated Urinary Tract Infection Clinical Trials

    Article • Clinical Infectious Diseases, August 2022, Oxford University Press (OUP)

    Dr Toshimitsu Hamasaki

  23. Editor’s Note

    Article • Statistics in Biopharmaceutical Research, July 2022, Taylor & Francis

    Dr Toshimitsu Hamasaki

  24. Bridging Therapy With Heparin Before Starting Rivaroxaban in Ischemic Stroke or Transient Ischemic Attack With Non-Valvular Atrial Fibrillation

    Article • Circulation Journal, May 2022, Japanese Circulation Society

    Dr Toshimitsu Hamasaki

  25. Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial

    Article • Trials, May 2022, Springer Science + Business Media

    Dr Toshimitsu Hamasaki

  26. A Desirability of Outcome Ranking Analysis of a Randomized Clinical Trial Comparing Seven Versus Fourteen Days of Antibiotics for Uncomplicated Gram-Negative Bloodstream Infection

    Article • Open Forum Infectious Diseases, April 2022, Oxford University Press (OUP)

    Dr Toshimitsu Hamasaki

  27. Early initiation of rivaroxaban after reperfusion therapy for stroke patients with nonvalvular atrial fibrillation

    Article • PLOS One, April 2022, PLOS

    Dr Toshimitsu Hamasaki

  28. Statistics in Medicine

    Article • The American Statistician, April 2022, Taylor & Francis

    Dr Toshimitsu Hamasaki

  29. Editor’s Note

    Article • Statistics in Biopharmaceutical Research, April 2022, Taylor & Francis

    Dr Toshimitsu Hamasaki

  30. Statistical Issues and Challenges in Clinical Trials for COVID-19 Treatments, Vaccines, Medical Devices and Diagnostics

    Article • Statistics in Biopharmaceutical Research, December 2021, Taylor & Francis

    Martin Posch, Dr Toshimitsu Hamasaki

  31. Editor’s Note

    Article • Statistics in Biopharmaceutical Research, September 2021, Taylor & Francis

    Dr Toshimitsu Hamasaki

  32. ASPECTS-Region-Dependent Functional Outcomes after Endovascular Therapy in Patients with Cardioembolic Stroke

    Article • Journal of Stroke and Cerebrovascular Diseases, July 2021, Elsevier

    Dr Toshimitsu Hamasaki

  33. Special Issue for Selected Articles From the ISBS2019: Statistical Innovation and Contribution in the Era of Precision Healthcare

    Article • Statistics in Biopharmaceutical Research, April 2021, Taylor & Francis

    Dr Toshimitsu Hamasaki

  34. Statistics in Biopharmaceutical Research Best Papers Award

    Article • Statistics in Biopharmaceutical Research, April 2021, Taylor & Francis

    Dr Toshimitsu Hamasaki

  35. Sex Differences in Management and Outcomes of Cardioembolic Stroke: Post HOC Analyses of the RELAXED Study

    Article • Journal of Stroke and Cerebrovascular Diseases, April 2021, Elsevier

    Dr Toshimitsu Hamasaki

  36. On selecting the critical boundary functions in group-sequential trials with two time-to-event outcomes

    Article • Contemporary Clinical Trials, February 2021, Elsevier

    Dr Toshimitsu Hamasaki

  37. Editorial: Roles of Hypothesis Testing, p-Values and Decision Making in Biopharmaceutical Research

    Article • Statistics in Biopharmaceutical Research, January 2021, Taylor & Francis

    Dr Toshimitsu Hamasaki

  38. Influence of Induction Therapy Using Basiliximab With Delayed Tacrolimus Administration in Heart Transplant Recipients　― Comparison With Standard Tacrolimus-Based Triple Immunosuppression ―

    Article • Circulation Journal, November 2020, Japanese Circulation Society

    Dr Toshimitsu Hamasaki

  39. Sequential Multiple Assignment Randomized Trials for COMparing Personalized Antibiotic StrategieS (SMART COMPASS): Design Considerations

    Article • Statistics in Biopharmaceutical Research, November 2020, Taylor & Francis

    Dr Toshimitsu Hamasaki

  40. Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging: systematic review and meta-analysis of individual patient data

    Article • The Lancet, November 2020, Elsevier

    Director of the stroke unit, DMSci, clinical research associate professor Helle K. Iversen, Professor Malcolm R Macleod, Dr Toshimitsu Hamasaki

  41. Statistical Challenges in the Conduct and Management of Ongoing Clinical Trials During the COVID-19 Pandemic

    Article • Statistics in Biopharmaceutical Research, October 2020, Taylor & Francis

    Martin Posch, Dr Toshimitsu Hamasaki

  42. A Novel Extracorporeal Continuous-Flow Ventricular Assist System for Patients With Advanced Heart Failure　― Initial Clinical Experience ―

    Article • Circulation Journal, June 2020, Japanese Circulation Society

    Dr Toshimitsu Hamasaki

  43. The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design

    Article • BMJ, June 2020, BMJ

    Dr Toshimitsu Hamasaki

  44. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design

    Article • Trials, June 2020, Springer Science + Business Media

    Dr Toshimitsu Hamasaki

  45. “BAX602” in Preventing Surgical Adhesion after Extracorporeal Ventricular Assist Device Implantation for Refractory Congestive Heart Failure: Study Protocol for a Multicenter Randomized Clinical Trial

    Article • Cardiovascular Drugs and Therapy, May 2020, Springer Science + Business Media

    Dr Toshimitsu Hamasaki

  46. Thrombolysis With Alteplase at 0.6 mg/kg for Stroke With Unknown Time of Onset

    Article • Stroke, May 2020, Wolters Kluwer Health

    Dr Toshimitsu Hamasaki

  47. Does a computed tomography-based navigation system reduce the risk of dislocation after total hip arthroplasty in patients with osteonecrosis of the femoral head? A propensity score analysis

    Article • Journal of Artificial Organs, February 2020, Springer Science + Business Media

    Dr Toshimitsu Hamasaki

  48. Analysis of ordered composite endpoints

    Article • Statistics in Medicine, December 2019, Wiley

    Dr Toshimitsu Hamasaki

  49. Landiolol, an ultra-short acting beta-1 blocker, for preventing postoperative lung cancer recurrence: study protocol for a phase III, multicenter randomized trial with two parallel groups of patients

    Article • Trials, December 2019, Springer Science + Business Media

    Dr Toshimitsu Hamasaki

  50. Interim Monitoring for Futility in Clinical Trials With Two Co-Primary Endpoints Using Prediction

    Article • Statistics in Biopharmaceutical Research, November 2019, Taylor & Francis

    Toshimitsu Hamasaki, Scott -R Evans Evans, Dr Toshimitsu Hamasaki

  51. Antenatal Therapy for Fetal Supraventricular Tachyarrhythmias

    Article • Journal of the American College of Cardiology, August 2019, Elsevier

    Dr Toshimitsu Hamasaki

  52. Association of CYP2C19 Polymorphisms With Clopidogrel Reactivity and Clinical Outcomes in Chronic Ischemic Stroke

    Article • Circulation Journal, May 2019, Japanese Circulation Society

    Dr Toshimitsu Hamasaki

  53. Development and Validation of an Ischemic and Bleeding Risk Evaluation Tool in East Asian Patients Receiving Percutaneous Coronary Intervention

    Article • Thrombosis and Haemostasis, May 2019, Thieme Publishing Group

    Dr Toshimitsu Hamasaki

  54. Evaluating the safety and technical effectiveness of a newly developed intravascular ’flow isolator' stent for the treatment of intracranial aneurysms: study protocol for a first-in-human single-arm multiple-site clinical trial in Japan

    Article • BMJ Open, May 2019, BMJ

    Dr Toshimitsu Hamasaki

  55. Group-sequential logrank methods for trial designs using bivariate non-competing event-time outcomes

    Article • Lifetime Data Analysis, April 2019, Springer Science + Business Media

    Dr Toshimitsu Hamasaki

  56. Effects of Teneligliptin on the Progressive Left Ventricular Diastolic Dysfunction in Patients with Type 2 Diabetes Mellitus in Open-Label, Marker-Stratified Randomized, Parallel-Group Comparison, Standard Treatment-Controlled Multicenter Trial (TOPLEV...

    Article • Cardiovascular Drugs and Therapy, March 2019, Springer Science + Business Media

    Dr Toshimitsu Hamasaki

  57. Recombinant thrombomodulin for acute exacerbation in idiopathic interstitial pneumonias

    Article • Respirology, March 2019, Wiley

    Dr Toshimitsu Hamasaki

  58. Rivaroxaban administration after acute ischemic stroke: The RELAXED study

    Article • PLOS One, February 2019, PLOS

    Dr Toshimitsu Hamasaki

  59. Incidence and risk factors of hepatocellular carcinoma change over time in patients with hepatitis C virus infection who achieved sustained virologic response

    Article • Hepatology Research, February 2019, Wiley

    Dr Toshimitsu Hamasaki

  60. The Survival Benefit of a Novel Trauma Workflow that Includes Immediate Whole-body Computed Tomography, Surgery, and Interventional Radiology, All in One Trauma Resuscitation Room

    Article • Annals of Surgery, February 2019, Wolters Kluwer Health

    Dr Toshimitsu Hamasaki

  61. Thrombolysis with Alteplase at 0·6 mg/kg for Acute FLAIR-Negative Stroke with Unknown Time of Onset: THAWS Randomized Controlled Trial

    Article • SSRN Electronic Journal, January 2019, Elsevier

    Dr Toshimitsu Hamasaki

  62. External Validation of the Two Newly Proposed Criteria for Assessing Coagulopathy in Sepsis

    Article • Thrombosis and Haemostasis, December 2018, Thieme Publishing Group

    Dr Toshimitsu Hamasaki

  63. Development process of a consensus-driven CONSORT extension for randomised trials using an adaptive design

    Article • BMC Medicine, November 2018, Springer Science + Business Media

    Dr Toshimitsu Hamasaki

  64. Sequential, Multiple-Assignment, Randomized Trials for COMparing Personalized Antibiotic StrategieS (SMART-COMPASS)

    Article • Clinical Infectious Diseases, October 2018, Oxford University Press (OUP)

    Dr Toshimitsu Hamasaki

  65. Cardiovascular Outcomes in Patients With Previous Myocardial Infarction and Mild Diabetes Mellitus Following Treatment With Pioglitazone

    Article • EClinicalMedicine, October 2018, Elsevier

    Dr Toshimitsu Hamasaki

  66. Effect of the Hybrid Emergency Room System on Functional Outcome in Patients with Severe Traumatic Brain Injury

    Article • World Neurosurgery, October 2018, Elsevier

    Dr Toshimitsu Hamasaki

  67. Japanese Antibacterial Drug Management for Cardiac Sarcoidosis (J-ACNES): A multicenter, open-label, randomized, controlled study

    Article • Journal of Arrhythmia, August 2018, Wiley

    Dr Toshimitsu Hamasaki

  68. Rationale and Design of the Multicenter Trial on Japan Working Group on the Effects of Angiotensin Receptor Blockers Selection (Azilsartan vs. Candesartan) on Diastolic Function in the Patients Suffering from Heart Failure with Preserved Ejection Fract...

    Article • Cardiovascular Drugs and Therapy, July 2018, Springer Science + Business Media

    Dr Toshimitsu Hamasaki

  69. In Reply to “ Streptococcus mutans with Collagen-Binding Protein: From Oral Cavity to Brain”

    Article • World Neurosurgery, July 2018, Elsevier

    Dr Toshimitsu Hamasaki

  70. Assessment of Safety and Effectiveness of the Extracorporeal Continuous-Flow Ventricular Assist Device (BR16010) Use as a Bridge-to-Decision Therapy for Severe Heart Failure or Refractory Cardiogenic Shock: Study Protocol for Single-Arm Non-randomized,...

    Article • Cardiovascular Drugs and Therapy, June 2018, Springer Science + Business Media

    Dr Toshimitsu Hamasaki

  71. A Potential New Risk Factor for Stroke: Streptococcus Mutans With Collagen-Binding Protein

    Article • World Neurosurgery, May 2018, Elsevier

    Dr Toshimitsu Hamasaki

  72. Sustained Effectiveness of Cilostazol After Endovascular Treatment of Femoropopliteal Lesions: Midterm Follow-up From the Sufficient Treatment of Peripheral Intervention by Cilostazol (STOP-IC) Study

    Article • Journal of Endovascular Therapy, April 2018, SAGE Publications

    Dr Toshimitsu Hamasaki

  73. An Exploratory Study of Dapagliflozin for the Attenuation of Albuminuria in Patients with Heart Failure and Type 2 Diabetes Mellitus (DAPPER)

    Article • Cardiovascular Drugs and Therapy, March 2018, Springer Science + Business Media

    Dr Toshimitsu Hamasaki

  74. Vascular response to biolimus A-9 eluting stent in patients with shorter and prolonged dual antiplatelet therapy: optical coherence tomography sub-study of the NIPPON trial

    Article • Heart and Vessels, February 2018, Springer Science + Business Media

    Dr Toshimitsu Hamasaki

  75. Effect of eicosapentaenoic acid/docosahexaenoic acid on coronary high-intensity plaques detected with non-contrast T1-weighted imaging (the AQUAMARINE EPA/DHA study): study protocol for a randomized controlled trial

    Article • Trials, January 2018, Springer Science + Business Media

    Dr Toshimitsu Hamasaki

  76. Screening itself for disseminated intravascular coagulation may reduce mortality in sepsis: A nationwide multicenter registry in Japan

    Article • Thrombosis Research, January 2018, Elsevier

    Dr Toshimitsu Hamasaki

  77. Antenatal Antiarrhythmic Treatment for Fetal Tachyarrhythmias: A Prospective Multicentre Trial

    Article • SSRN Electronic Journal, January 2018, Elsevier

    Dr Toshimitsu Hamasaki

  78. Cardiovascular Outcomes in Patients with Previous Myocardial Infarction and Mild Diabetes Mellitus Following Treatment with Pioglitazone -Reports from the Japan Working Group for the Assessment Whether Pioglitazone Protects Dm Patients Against Re-Infar...

    Article • SSRN Electronic Journal, January 2018, Elsevier

    Dr Toshimitsu Hamasaki

  79. Rationale and Design of Low-dose Administration of Carperitide for Acute Heart Failure (LASCAR-AHF)

    Article • Cardiovascular Drugs and Therapy, November 2017, Springer Science + Business Media

    Dr Toshimitsu Hamasaki

  80. Design, data monitoring, and analysis of clinical trials with co-primary endpoints: A review

    Article • Journal of Biopharmaceutical Statistics, October 2017, Taylor & Francis

    Dr Toshimitsu Hamasaki

  81. Metabolic tumor volume of primary tumor predicts survival better than T classification in the larynx preservation approach

    Article • Cancer Science, August 2017, Wiley

    Dr Toshimitsu Hamasaki

  82. Antenatal antiarrhythmic treatment for fetal tachyarrhythmias: a study protocol for a prospective multicentre trial

    Article • BMJ Open, August 2017, BMJ

    Dr Toshimitsu Hamasaki

  83. Does Treatment of Impaired Glucose Tolerance Improve Cardiovascular Outcomes in Patients with Previous Myocardial Infarction?

    Article • Cardiovascular Drugs and Therapy, August 2017, Springer Science + Business Media

    Dr Toshimitsu Hamasaki

  84. Sample size determination for a specific region in multiregional clinical trials with multiple co-primary endpoints

    Article • PLOS One, June 2017, PLOS

    Dr Toshimitsu Hamasaki

  85. Impact of Gram stain results on initial treatment selection in patients with ventilator-associated pneumonia: a retrospective analysis of two treatment algorithms

    Article • Critical Care, June 2017, Springer Science + Business Media

    Dr Toshimitsu Hamasaki

  86. Dual Antiplatelet Therapy for 6 Versus 18 Months After Biodegradable Polymer Drug-Eluting Stent Implantation

    Article • JACC Cardiovascular Interventions, June 2017, Elsevier

    Dr Toshimitsu Hamasaki

  87. Plasma aldosterone level within the normal range is less associated with cardiovascular and cerebrovascular risk in primary aldosteronism

    Article • Journal of Hypertension, May 2017, Wolters Kluwer Health

    Dr Toshimitsu Hamasaki

  88. A multicenter randomized controlled trial of surgery alone or surgery with atrial natriuretic peptide in lung cancer surgery: study protocol for a randomized controlled trial

    Article • Trials, April 2017, Springer Science + Business Media

    Dr Toshimitsu Hamasaki

  89. Does the pathophysiology of heart failure prime the incidence of cancer?

    Article • Hypertension Research, April 2017, Springer Science + Business Media

    Dr Toshimitsu Hamasaki

  90. A multicenter study of the need of additional freezing for cryoballoon ablation in patients with atrial fibrillation: The AD-Balloon study

    Article • Journal of Arrhythmia, April 2017, Wiley

    Dr Toshimitsu Hamasaki

  91. Low partial pressure of end-tidal carbon dioxide predicts left ventricular assist device implantation in patients with advanced chronic heart failure

    Article • International Journal of Cardiology, March 2017, Elsevier

    Dr Toshimitsu Hamasaki

  92. Classification of idiopathic interstitial pneumonias using anti–myxovirus resistance-protein 1 autoantibody

    Article • Scientific Reports, February 2017, Springer Science + Business Media

    Kenji Mizuguchi, Dr Toshimitsu Hamasaki

  93. Sizing clinical trials when comparing bivariate time-to-event outcomes

    Article • Statistics in Medicine, January 2017, Wiley

    Dr Toshimitsu Hamasaki

  94. Interview with Professor Geert Molenberghs

    Article • CHANCE, January 2017, Taylor & Francis

    Dr Toshimitsu Hamasaki

  95. Risk stratification based on nutritional screening on admission: Three-year clinical outcomes in hospitalized patients with acute heart failure syndrome

    Article • Journal of Cardiology, November 2016, Elsevier

    Dr Toshimitsu Hamasaki

  96. Long-Term Impact of Postoperative Complications on Cancer Recurrence Following Lung Cancer Surgery

    Article • Annals of Surgical Oncology, October 2016, Springer Science + Business Media

    Dr Toshimitsu Hamasaki

  97. Interim evaluation of efficacy or futility in group-sequential trials with multiple co-primary endpoints

    Article • Biometrical Journal, October 2016, Wiley

    Dr Toshimitsu Hamasaki

  98. Benefit profile of anticoagulant therapy in sepsis: a nationwide multicentre registry in Japan

    Article • Critical Care, July 2016, Springer Science + Business Media

    Dr Toshimitsu Hamasaki

  99. Effectiveness of sarpogrelate after endovascular treatment for femoropopliteal artery disease: ESPALIER study

    Article • Cardiovascular Intervention and Therapeutics, July 2016, Springer Science + Business Media

    Dr Toshimitsu Hamasaki

  100. Design and Rationale of the RELAXED (Recurrent Embolism Lessened by rivaroxaban, an Anti-Xa agent, of Early Dosing for acute ischemic stroke and transient ischemic attack with atrial fibrillation) Study

    Article • Journal of Stroke and Cerebrovascular Diseases, June 2016, Elsevier

    Dr Toshimitsu Hamasaki

  101. Subclinical elevation of high-sensitive troponin T levels at the convalescent stage is associated with increased 5-year mortality after ST-elevation myocardial infarction

    Article • Journal of Cardiology, April 2016, Elsevier

    Dr Toshimitsu Hamasaki

  102. Group-sequential three-arm noninferiority clinical trial designs

    Article • Journal of Biopharmaceutical Statistics, February 2016, Taylor & Francis

    Dr Toshimitsu Hamasaki

  103. Low total cholesterol and high total bilirubin are associated with prognosis in patients with prolonged sepsis

    Article • Journal of Critical Care, February 2016, Elsevier

    Dr Toshimitsu Hamasaki

  104. Group-Sequential Clinical Trials with Multiple Co-Objectives

    Article • January 2016, Springer Science + Business Media

    Dr Toshimitsu Hamasaki

  105. Clinical Impact of Ventricular Tachycardia and/or Fibrillation During the Acute Phase of Acute Myocardial Infarction on In-Hospital and 5-Year Mortality Rates in the Percutaneous Coronary Intervention Era

    Article • Circulation Journal, January 2016, Japanese Circulation Society

    Dr Toshimitsu Hamasaki

  106. Regression analysis

    Article • Drug Delivery System, January 2016, Japan Society of Drug Delivery System

    Dr Toshimitsu Hamasaki

  107. Nur77 gene expression levels were involved in different ACTH-secretion autonomy between Cushing’s disease and subclinical Cushing’s disease

    Article • Endocrine Journal, January 2016, Japan Endocrine Society

    Dr Toshimitsu Hamasaki

  108. The significance of G-CSF expression and myeloid-derived suppressor cells in the chemoresistance of uterine cervical cancer

    Article • Scientific Reports, December 2015, Springer Science + Business Media

    Dr Toshimitsu Hamasaki

  109. Influence of the Lactotripeptides Isoleucine–Proline–Proline and Valine–Proline–Proline on Systolic Blood Pressure in Japanese Subjects: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    Article • PLOS One, November 2015, PLOS

    Dr Toshimitsu Hamasaki

  110. 3-Year Outcomes of the OLIVE Registry, a Prospective Multicenter Study of Patients With Critical Limb Ischemia

    Article • JACC Cardiovascular Interventions, September 2015, Elsevier

    Dr Toshimitsu Hamasaki

  111. The impact of an inosine triphosphate pyrophosphatase genotype on bilirubin increase in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin

    Article • Journal of Gastroenterology, July 2015, Springer Science + Business Media

    Dr Toshimitsu Hamasaki

  112. Clinical and Histologic Analysis of the Efficacy of Topical Rapamycin Therapy Against Hypomelanotic Macules in Tuberous Sclerosis Complex

    Article • JAMA Dermatology, July 2015, American Medical Association (AMA)

    Dr Toshimitsu Hamasaki

  113. Reducing unnecessary measurements in clinical trials with multiple primary endpoints

    Article • Journal of Biopharmaceutical Statistics, June 2015, Taylor & Francis

    Dr Toshimitsu Hamasaki

  114. Design and Evaluation of New Unified Criteria for Disseminated Intravascular Coagulation Based on the Japanese Association for Acute Medicine Criteria

    Article • Clinical and Applied Thrombosis/Hemostasis, June 2015, SAGE Publications

    Dr Toshimitsu Hamasaki

  115. Sample Size Considerations in Clinical Trials When Comparing Two Interventions Using Multiple Co-Primary Binary Relative Risk Contrasts

    Article • Statistics in Biopharmaceutical Research, April 2015, Taylor & Francis

    Dr Toshimitsu Hamasaki

  116. Prognostic significance of systemic neutrophil and leukocyte alterations in surgically treated endometrial cancer patients: A monoinstitutional study

    Article • Gynecologic Oncology, April 2015, Elsevier

    Dr Toshimitsu Hamasaki

  117. Ossification of the Posterior Longitudinal Ligament of the Cervical Spine in 3161 Patients

    Article • Spine, April 2015, Wolters Kluwer Health

    Dr Toshimitsu Hamasaki

  118. Recombinant human soluble thrombomodulin in severe sepsis: a systematic review and meta-analysis

    Article • Journal of Thrombosis and Haemostasis, March 2015, Wiley

    Dr Toshimitsu Hamasaki

  119. Postprocedural Skin Perfusion Pressure Correlates With Clinical Outcomes 1 Year After Endovascular Therapy for Patients With Critical Limb Ischemia

    Article • Angiology, February 2015, SAGE Publications

    Dr Toshimitsu Hamasaki

  120. B‐Type Natriuretic Peptide‐Guided Risk Assessment for Postoperative Complications in Lung Cancer Surgery

    Article • Extremophiles, January 2015, Wiley

    Dr Toshimitsu Hamasaki

  121. Group-Sequential Strategies in Clinical Trials with Multiple Co-Primary Outcomes

    Article • Statistics in Biopharmaceutical Research, January 2015, Taylor & Francis

    Dr Toshimitsu Hamasaki

  122. Sample Size Determination in Clinical Trials with Multiple Endpoints

    Article • January 2015, Springer Science + Business Media

    Dr Toshimitsu Hamasaki

  123. Two-sample tests for comparing means

    Article • Drug Delivery System, January 2015, Japan Society of Drug Delivery System

    Dr Toshimitsu Hamasaki

  124. Benefit profile of recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis

    Article • Critical Care, January 2015, Springer Science + Business Media

    Dr Toshimitsu Hamasaki

  125. Clinical significance of fluctuations in thyroid hormones after surgery for Cushing’s syndrome

    Article • Endocrine Journal, January 2015, Japan Endocrine Society

    Dr Toshimitsu Hamasaki

  126. Group-Sequential Designs When Considering Two Binary Outcomes as Co-Primary Endpoints

    Article • January 2015, Springer Science + Business Media

    Dr Toshimitsu Hamasaki

  127. Analysis of survival data

    Article • Drug Delivery System, January 2015, Japan Society of Drug Delivery System

    Dr Toshimitsu Hamasaki

  128. Fundamentals of statistical analysis in biomedical research：Avoiding statical pitfalls

    Article • Drug Delivery System, January 2015, Japan Society of Drug Delivery System

    Dr Toshimitsu Hamasaki

  129. Multiple comparisons: comparing more than two treatments

    Article • Drug Delivery System, January 2015, Japan Society of Drug Delivery System

    Dr Toshimitsu Hamasaki

  130. Two-sample tests for comparing proportions

    Article • Drug Delivery System, January 2015, Japan Society of Drug Delivery System

    Dr Toshimitsu Hamasaki

  131. Different serial changes in the neointimal condition of sirolimus-eluting stents and paclitaxel-eluting stents: an optical coherence tomographic study

    Article • EuroIntervention, December 2014, Europa Digital & Publishing

    Dr Toshimitsu Hamasaki

  132. Impact of alpha-fetoprotein on hepatocellular carcinoma development during entecavir treatment of chronic hepatitis B virus infection

    Article • Journal of Gastroenterology, November 2014, Springer Science + Business Media

    Dr Toshimitsu Hamasaki

  133. Outcomes of ESD for patients with early gastric cancer and comorbid liver cirrhosis: a propensity score analysis

    Article • Surgical Endoscopy, October 2014, Springer Science + Business Media

    Dr Toshimitsu Hamasaki, Dr Tsutomu Nishida

  134. Design Challenges for Heart Failure Prevention Clinical Trials: Adaptive Design Approach

    Article • Journal of Cardiac Failure, October 2014, Elsevier

    Dr Toshimitsu Hamasaki

  135. Portable system for monitoring of regional cerebral oxygen saturation during prehospital cardiopulmonary resuscitation: a pilot study

    Article • Acute Medicine & Surgery, October 2014, Wiley

    Dr Toshimitsu Hamasaki

  136. Combinations of olmesartan and a calcium channel blocker or a diuretic in elderly hypertensive patients

    Article • Journal of Hypertension, October 2014, Wolters Kluwer Health

    Tomoko Hamasaki, Dr Toshimitsu Hamasaki

  137. Impact of cardiopulmonary complications of lung cancer surgery on long-term outcomes

    Article • Surgery Today, September 2014, Springer Science + Business Media

    Dr Toshimitsu Hamasaki

  138. Reduced risk of recurrent myocardial infarction in homozygous carriers of the chromosome 9p21 rs1333049 C risk allele in the contemporary percutaneous coronary intervention era: a prospective observational study

    Article • BMJ Open, August 2014, BMJ

    Dr Toshimitsu Hamasaki

  139. THrombolysis for Acute Wake-up and Unclear-Onset Strokes with Alteplase at 0·6 mg/kg (THAWS) Trial

    Article • International Journal of Stroke, August 2014, SAGE Publications

    Dr Toshimitsu Hamasaki

  140. Difference in Left Ventricular Mass Index Between Hypertensive Patients With and Without Renal Artery Stenosis by Propensity Score Analysis

    Article • Journal of Clinical Hypertension, July 2014, Wiley

    Dr Toshimitsu Hamasaki

  141. Volumetric PET/CT parameters predict local response of head and neck squamous cell carcinoma to chemoradiotherapy

    Article • Cancer Medicine, July 2014, Wiley

    Dr Toshimitsu Hamasaki

  142. Comparison of 5-Year Survival After Acute Myocardial Infarction Using Angiotensin-Converting Enzyme Inhibitor Versus Angiotensin II Receptor Blocker

    Article • The American Journal of Cardiology, July 2014, Elsevier

    Dr Toshimitsu Hamasaki

  143. Coronary triglyceride deposition in contemporary advanced diabetics

    Article • Pathology International, July 2014, Wiley

    Dr Toshimitsu Hamasaki

  144. Post-treatment Levels of α-Fetoprotein Predict Incidence of Hepatocellular Carcinoma After Interferon Therapy

    Article • Clinical Gastroenterology and Hepatology, July 2014, Elsevier

    Dr Toshimitsu Hamasaki

  145. Uterine Cervical Cancer Displaying Tumor-Related Leukocytosis: A Distinct Clinical Entity With Radioresistant Feature

    Article • JNCI Journal of the National Cancer Institute, June 2014, Oxford University Press (OUP)

    Dr Toshimitsu Hamasaki

  146. Association of lifestyle-related factors with circadian onset patterns of acute myocardial infarction: a prospective observational study in Japan

    Article • BMJ Open, June 2014, BMJ

    Dr Toshimitsu Hamasaki

  147. Importance of optimal local uterine blood flow for implantation

    Article • Journal of Obstetrics and Gynaecology Research, June 2014, Wiley

    Dr Toshimitsu Hamasaki

  148. Combination Treatment With Trabectedin and Irinotecan or Topotecan Has Synergistic Effects Against Ovarian Clear Cell Carcinoma Cells

    Article • International Journal of Gynecological Cancer, June 2014, Elsevier

    Dr Toshimitsu Hamasaki

  149. Possible modification of Alzheimer’s disease by statins in midlife: interactions with genetic and non-genetic risk factors

    Article • Frontiers in Aging Neuroscience, April 2014, Frontiers

    Dr Toshimitsu Hamasaki

  150. Rapid and Sustained Long-Term Decrease of Fecal Short-Chain Fatty Acids in Critically Ill Patients With Systemic Inflammatory Response Syndrome

    Article • Journal of Parenteral and Enteral Nutrition, April 2014, SAGE Publications

    Dr Toshimitsu Hamasaki

  151. Perioperative Landiolol Administration reduces Atrial Fibrillation after Cardiac Surgery: A Meta-analysis of Randomized Controlled Trials

    Article • Advances in Therapy, April 2014, Springer Science + Business Media

    Dr Toshimitsu Hamasaki

  152. Clinical impact of acute hyperglycemia on development of diabetes mellitus in non-diabetic patients with acute myocardial infarction

    Article • Journal of Cardiology, April 2014, Elsevier

    Dr Toshimitsu Hamasaki

  153. Sample size determination in group‐sequential clinical trials with two co‐primary endpoints

    Article • Statistics in Medicine, March 2014, Wiley

    Dr Toshimitsu Hamasaki

  154. 11β-Hydroxysteroid Dehydrogenase 1 Specific Inhibitor Increased Dermal Collagen Content and Promotes Fibroblast Proliferation

    Article • PLOS One, March 2014, PLOS

    Dr Toshimitsu Hamasaki

  155. Altered balance of the aminogram in patients with sepsis – The relation to mortality

    Article • Clinical Nutrition, February 2014, Elsevier

    Dr Toshimitsu Hamasaki

  156. Characterization of Patients With Angioscopically-Detected In-Stent Mural Thrombi

    Article • Circulation Journal, January 2014, Japanese Circulation Society

    Dr Toshimitsu Hamasaki

  157. Renin-Angiotensin-Aldosterone System Polymorphisms and 5-Year Mortality in Survivors of Acute Myocardial Infarction

    Article • International Heart Journal, January 2014, International Heart Journal (Japanese Heart Journal)

    Dr Toshimitsu Hamasaki

  158. Rapid decline in bone turnover markers but not bone mineral density in acromegalic patients after transsphenoidal surgery

    Article • Endocrine Journal, January 2014, Japan Endocrine Society

    Dr Toshimitsu Hamasaki

  159. Correction: Trends in the Prevalence of Tuberous Sclerosis Complex Manifestations: An Epidemiological Study of 166 Japanese Patients

    Article • PLOS One, December 2013, PLOS

    Dr Toshimitsu Hamasaki

  160. Outcome prediction model for severe traumatic brain injury

    Article • Acute Medicine & Surgery, October 2013, Wiley

    Dr Toshimitsu Hamasaki

  161. Synovial joint fluid cytokine levels in hip disease

    Article • Rheumatology, October 2013, Oxford University Press (OUP)

    Dr Toshimitsu Hamasaki

  162. Living alone and risk of cardiovascular events following discharge after acute myocardial infarction in Japan

    Article • Journal of Cardiology, October 2013, Elsevier

    Dr Toshimitsu Hamasaki

  163. Impact on survival of whole-body computed tomography before emergency bleeding control in patients with severe blunt trauma

    Article • Critical Care, August 2013, Springer Science + Business Media

    Dr Toshimitsu Hamasaki

  164. Response to the Letter by Devaux et al

    Article • Circulation Research, August 2013, Wolters Kluwer Health

    Dr Toshimitsu Hamasaki

  165. Authors’ reply

    Article • Biometrical Journal, July 2013, Wiley

    Dr Toshimitsu Hamasaki

  166. Circulating p53-Responsive MicroRNAs Are Predictive Indicators of Heart Failure After Acute Myocardial Infarction

    Article • Circulation Research, June 2013, Wolters Kluwer Health

    Dr Toshimitsu Hamasaki

  167. Maximal Chemiluminescent Intensity in Response to Lipopolysaccharide Assessed by Endotoxin Activity Assay on Admission Day Predicts Mortality in Patients With Sepsis*

    Article • Critical Care Medicine, June 2013, Wolters Kluwer Health

    Dr Toshimitsu Hamasaki

  168. Trends in the Prevalence of Tuberous Sclerosis Complex Manifestations: An Epidemiological Study of 166 Japanese Patients

    Article • PLOS One, May 2013, PLOS

    Dr Toshimitsu Hamasaki

  169. Cilostazol Reduces Angiographic Restenosis After Endovascular Therapy for Femoropopliteal Lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol Study

    Article • Circulation, May 2013, Wolters Kluwer Health

    Dr Toshimitsu Hamasaki

  170. Partition testing in confirmatory adaptive designs with structured objectives

    Article • Biometrical Journal, May 2013, Wiley

    Dr Toshimitsu Hamasaki

  171. Sleep quality in patients with alopecia areata: questionnaire-based study

    Article • International Journal of Dermatology, March 2013, Wiley

    Dr Toshimitsu Hamasaki

  172. L-threo-3,4-dihydroxyphenylserine (L-DOPS) co-administered with entacapone improves freezing of gait in Parkinson’s disease

    Article • Medical Hypotheses, February 2013, Elsevier

    Dr Toshimitsu Hamasaki

  173. Impact of Beta Blockade Therapy on Long-Term Mortality After ST-Segment Elevation Acute Myocardial Infarction in the Percutaneous Coronary Intervention Era

    Article • The American Journal of Cardiology, February 2013, Elsevier

    Dr Toshimitsu Hamasaki

  174. Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis

    Article • Intensive Care Medicine, January 2013, Springer Science + Business Media

    Dr Toshimitsu Hamasaki

  175. Endovascular Treatment for Infrainguinal Vessels in Patients With Critical Limb Ischemia: OLIVE Registry, a Prospective, Multicenter Study in Japan With 12-Month Follow-up

    Article • Circulation Cardiovascular Interventions, January 2013, Wolters Kluwer Health

    Dr Toshimitsu Hamasaki

  176. A logrank test-based method for sizing clinical trials with two co-primary time-to-event endpoints

    Article • Biostatistics, January 2013, Oxford University Press (OUP)

    Dr Toshimitsu Hamasaki

  177. Aqueous Concentrations of Vascular Endothelial Growth Factor in Eyes with High Myopia with and without Choroidal Neovascularization

    Article • Journal of Ophthalmology, January 2013, Wiley

    Dr Toshimitsu Hamasaki

  178. Statistical Issues in Clinical Trials with Multiple Primary Endpoints

    Article • Japanese Journal of Biometrics, January 2013, The Biometric Society of Japan

    Dr Toshimitsu Hamasaki

  179. Incidence, Predictors, and Subsequent Mortality Risk of Recurrent Myocardial Infarction in Patients Following Discharge for Acute Myocardial Infarction

    Article • Circulation Journal, January 2013, Japanese Circulation Society

    Dr Toshimitsu Hamasaki

  180. DNA Damage in Rheumatoid Arthritis: An Age-Dependent Increase in the Lipid Peroxidation-Derived DNA Adduct, Heptanone-Etheno-2′-Deoxycytidine

    Article • Autoimmune Diseases, January 2013, Wiley

    Dr Toshimitsu Hamasaki

  181. Clinical Features of Young Patients with Olfactory Disorders

    Article • Practica Oto-Rhino-Laryngologica, January 2013, The Society of Practical Otolaryngology

    Dr Toshimitsu Hamasaki

  182. Reduction of Thoracic Aorta Motion Artifact With High-Pitch 128-Slice Dual-Source Computed Tomographic Angiography

    Article • Journal of Computer Assisted Tomography, January 2013, Wolters Kluwer Health

    Dr Toshimitsu Hamasaki

  183. Parkinsonian Rigidity Shows Variable Properties Depending on the Elbow Joint Angle

    Article • Parkinson s Disease, January 2013, Wiley

    Dr Toshimitsu Hamasaki

  184. Utility of serum squamous cell carcinoma antigen levels at the time of recurrent cervical cancer diagnosis in determining the optimal treatment choice

    Article • Journal of Gynecologic Oncology, January 2013, Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology and Colposcopy (KAMJE)

    Dr Toshimitsu Hamasaki

  185. Fast Wavelength Switching of Fully Heater-tuned CSG-DR Lasers

    Article • January 2013, Optical Society of America (OSA)

    Dr Toshimitsu Hamasaki

  186. Elevated Serum Heart-Type Fatty Acid-Binding Protein in the Convalescent Stage Predicts Long-Term Outcome in Patients Surviving Acute Myocardial Infarction

    Article • Circulation Journal, January 2013, Japanese Circulation Society

    Dr Toshimitsu Hamasaki

  187. Low Levels of Serum n-3 Polyunsaturated Fatty Acids Are Associated With Worse Heart Failure-Free Survival in Patients After Acute Myocardial Infarction

    Article • Circulation Journal, January 2013, Japanese Circulation Society

    Dr Toshimitsu Hamasaki

  188. Elevated White Blood Cell Count at the Time of Recurrence Diagnosis Is an Indicator of Short Survival in Patients With Recurrent Cervical Cancer

    Article • International Journal of Gynecological Cancer, November 2012, Elsevier

    Dr Toshimitsu Hamasaki

  189. Sample size determination for clinical trials with co‐primary outcomes: exponential event times

    Article • Pharmaceutical Statistics, October 2012, Wiley

    Dr Toshimitsu Hamasaki

  190. A subset of circulating microRNAs are predictive for cardiac death after discharge for acute myocardial infarction

    Article • Biochemical and Biophysical Research Communications, October 2012, Elsevier

    Dr Toshimitsu Hamasaki

  191. Is the transverse acetabular ligament a reliable cup orientation guide?

    Article • Acta Orthopaedica, September 2012, Acta Dermato-Venereologica

    Dr Toshimitsu Hamasaki

  192. INTRAOCULAR PRESSURE ELEVATION IS A DELAYED-ONSET COMPLICATION AFTER SUCCESSFUL VITRECTOMY FOR STAGES 4 AND 5 RETINOPATHY OF PREMATURITY

    Article • Retina, September 2012, Wolters Kluwer Health

    Dr Toshimitsu Hamasaki

  193. Adiponectin negatively correlates with alcoholic and non‐alcoholic liver dysfunction: Health check‐up study of Japanese men

    Article • Hepatology Research, July 2012, Wiley

    Dr Toshimitsu Hamasaki

  194. Sample size determination in clinical trials with multiple co-primary endpoints including mixed continuous and binary variables

    Article • Biometrical Journal, July 2012, Wiley

    Dr Toshimitsu Hamasaki

  195. Prognostic impact of fecal pH in critically ill patients

    Article • Critical Care, July 2012, Springer Science + Business Media

    Dr Toshimitsu Hamasaki

  196. Estimation of mouse fetal weight by ultrasonography: application from clinic to laboratory

    Article • Laboratory Animals, July 2012, SAGE Publications

    Dr Toshimitsu Hamasaki

  197. How Regular Visits and Preventive Programs Affect Onset of Adult Caries

    Article • Journal of Dental Research, June 2012, SAGE Publications

    Dr Toshimitsu Hamasaki

  198. Prediction of Progression-Free Survival and Response to Paclitaxel Plus Carboplatin in Patients With Recurrent or Advanced Cervical Cancer

    Article • International Journal of Gynecological Cancer, May 2012, Elsevier

    Dr Toshimitsu Hamasaki

  199. Recombinant human soluble thrombomodulin improves mortality and respiratory dysfunction in patients with severe sepsis

    Article • Journal of Trauma and Acute Care Surgery, May 2012, Wolters Kluwer Health

    Dr Toshimitsu Hamasaki

  200. A convenient formula for sample size calculations in clinical trials with multiple co‐primary continuous endpoints

    Article • Pharmaceutical Statistics, March 2012, Wiley

    Dr Toshimitsu Hamasaki

  201. Clinical Outcomes and Changes in Aqueous Vascular Endothelial Growth Factor Levels After Intravitreal Bevacizumab for Iris Neovascularization and Neovascular Glaucoma: A Retrospective Two-Dose Comparative Study

    Article • Journal of Ocular Pharmacology and Therapeutics, February 2012, Mary Ann Liebert Inc

    Dr Toshimitsu Hamasaki

  202. Oral treatment with nicorandil at discharge is associated with reduced mortality after acute myocardial infarction

    Article • Journal of Cardiology, January 2012, Elsevier

    Dr Toshimitsu Hamasaki

  203. Assessment of risk factors related to healthcare-associated methicillin-resistant Staphylococcus aureus infection at patient admission to an intensive care unit in Japan

    Article • BMC Infectious Diseases, November 2011, Springer Science + Business Media

    Dr Toshimitsu Hamasaki

  204. Association of low serum adiponectin levels with erosive esophagitis in men: an analysis of 2405 subjects undergoing physical check-ups

    Article • Journal of Gastroenterology, August 2011, Springer Science + Business Media

    Dr Toshimitsu Hamasaki

  205. P3‐403: Cognitive training on elderly japanese in osaka: Major outcome (ADAS) from prospective, randomized, open, blind‐endpoint trial

    Article • Alzheimer s & Dementia, July 2011, Wiley

    Dr Toshimitsu Hamasaki

  206. Pretreatment leukocytosis is an indicator of poor prognosis in patients with cervical cancer

    Article • Gynecologic Oncology, July 2011, Elsevier

    Dr Toshimitsu Hamasaki

  207. Prognostic indicators and outcome prediction model for patients with return of spontaneous circulation from cardiopulmonary arrest: The Utstein Osaka Project

    Article • Resuscitation, July 2011, Elsevier

    Dr Toshimitsu Hamasaki

  208. Risk assessment of dental caries by using Classification and Regression Trees

    Article • Journal of Dentistry, June 2011, Elsevier

    Dr Toshimitsu Hamasaki

  209. Pre-emptive contact precautions for intubated patients reduced healthcare-associated meticillin-resistant Staphylococcus aureus transmission and infection in an intensive care unit

    Article • Journal of Hospital Infection, June 2011, Elsevier

    Dr Toshimitsu Hamasaki

  210. Hybridization of magnetic excitations between quasi-one-dimensional spin chains and spin dimers in Cu 3 Mo 2 O 9 observed using inelastic neutron scattering

    Article • Physical Review B, May 2011, American Physical Society (APS)

    Dr Toshimitsu Hamasaki

  211. Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study

    Article • Critical Care, May 2011, Springer Science + Business Media

    Dr Toshimitsu Hamasaki

  212. Sample Size Determination in Superiority Clinical Trials with Multiple Co-Primary Correlated Endpoints

    Article • Journal of Biopharmaceutical Statistics, April 2011, Taylor & Francis

    Dr Toshimitsu Hamasaki

  213. Lower Serum Level of Adiponectin Is Associated with Increased Risk of Endoscopic Erosive Gastritis

    Article • Digestive Diseases and Sciences, March 2011, Springer Science + Business Media

    Dr Toshimitsu Hamasaki

  214. Clinical Trials, History of

    Article • January 2011, Springer Science + Business Media

    Dr Toshimitsu Hamasaki

  215. A simple modification of the Box and Cox transformation to scale stability and invariance

    Article • Journal of the Japanese Society of Computational Statistics, January 2011, Japanese Society of Computational Statistics

    Dr Toshimitsu Hamasaki

  216. A Note on Analysis of Ratio of Two Correlated Normal Variables

    Article • Ouyou toukeigaku, January 2011, Japanese Society of Applied Statistics

    Dr Toshimitsu Hamasaki

  217. Multicenter Survey with a Systematic Overview of Acute-Onset Endophthalmitis after Transconjunctival Microincision Vitrectomy Surgery

    Article • American Journal of Ophthalmology, November 2010, Elsevier

    Dr Toshimitsu Hamasaki

  218. Altered Gut Flora Are Associated with Septic Complications and Death in Critically Ill Patients with Systemic Inflammatory Response Syndrome

    Article • Digestive Diseases and Sciences, October 2010, Springer Science + Business Media

    Dr Toshimitsu Hamasaki

  219. Macular Pigment Optical Density in Central Serous Chorioretinopathy

    Article • Investigative Ophthalmology & Visual Science, October 2010, Association for Research in Vision and Ophthalmology (ARVO)

    Dr Toshimitsu Hamasaki

  220. Sample size determination in clinical trials with multiple co‐primary binary endpoints

    Article • Statistics in Medicine, August 2010, Wiley

    Dr Toshimitsu Hamasaki

  221. Immunogene therapy using immunomodulating HVJ-E vector augments anti-tumor effects in murine malignant glioma

    Article • Journal of Neuro-Oncology, August 2010, Springer Science + Business Media

    Dr Toshimitsu Hamasaki

  222. Practical issues and lessons learned from multi‐regional clinical trials via case examples: a Japanese perspective

    Article • Pharmaceutical Statistics, July 2010, Wiley

    Dr Toshimitsu Hamasaki

  223. O3‐04‐07: Cognitive training on elderly Japanese in Osaka: Major outcome (ADAS) from prospective, randomized, open, blind‐endpoint trial

    Article • Alzheimer s & Dementia, July 2010, Wiley

    Dr Toshimitsu Hamasaki

  224. Ocular Risk Factors for Choroidal Neovascularization in Pathologic Myopia

    Article • Investigative Ophthalmology & Visual Science, July 2010, Association for Research in Vision and Ophthalmology (ARVO)

    Dr Toshimitsu Hamasaki

  225. Practical application of cure mixture model for long-term censored survivor data from a withdrawal clinical trial of patients with major depressive disorder

    Article • BMC Medical Research Methodology, April 2010, Springer Science + Business Media

    Dr Toshimitsu Hamasaki

  226. Reduced carotid atherosclerosis in asthmatic patients treated with inhaled corticosteroids

    Article • European Respiratory Journal, April 2010, European Respiratory Society (ERS)

    Dr Toshimitsu Hamasaki

  227. Box and Cox power-transformation to additivity and homoscedasticity in regression

    Article • Journal of the Japanese Society of Computational Statistics, January 2010, Japanese Society of Computational Statistics

    Dr Toshimitsu Hamasaki

  228. <i>KIBRA</i> Genetic Polymorphism Influences Episodic Memory in Alzheimer’s Disease, but Does Not Show Association with Disease in a Japanese Cohort

    Article • Dementia and Geriatric Cognitive Disorders, January 2010, Karger Publishers

    Dr Toshimitsu Hamasaki

  229. Intravitreal Bevacizumab vs Sub-Tenon Triamcinolone Acetonide for Choroidal Neovascularization Attributable to Pathologic Myopia

    Article • American Journal of Ophthalmology, October 2009, Elsevier

    Dr Toshimitsu Hamasaki

  230. Immunotherapy of ovarian cancer with cell wall skeleton of Mycobacterium bovis Bacillus Calmette‐Guérin: Effect of lymphadenectomy

    Article • Cancer Science, September 2009, Wiley

    Dr Toshimitsu Hamasaki

  231. Influence of voluntary control of masticatory side and rhythm on cerebral hemodynamics

    Article • Clinical Oral Investigations, August 2009, Springer Science + Business Media

    Dr Toshimitsu Hamasaki

  232. Opening velocity, a novel parameter, for finger tapping test in patients with Parkinson's disease

    Article • Parkinsonism & Related Disorders, July 2009, Elsevier

    Dr Toshimitsu Hamasaki

  233. A quantitative characterization of postural sway during human quiet standing using a thin pressure distribution measurement system

    Article • Gait & Posture, June 2009, Elsevier

    Dr Toshimitsu Hamasaki

  234. Prognostic Indicators and Outcome Prediction Model for Severe Traumatic Brain Injury

    Article • Journal of Trauma and Acute Care Surgery, February 2009, Wolters Kluwer Health

    Dr Toshimitsu Hamasaki

  235. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials

    Article • The Lancet, October 2007, Elsevier

    Dr Toshimitsu Hamasaki

  236. Task-induced activation and hemispheric dominance in cerebral circulation during gum chewing

    Article • Deutsche Zeitschrift für Nervenheilkunde, October 2007, Springer Science + Business Media

    Dr Toshimitsu Hamasaki

  237. HLA-DR-negative AML (M1 and M2): FLT3 mutations (ITD and D835) and cell-surface antigen expression

    Article • Leukemia Research, July 2007, Elsevier

    Dr Toshimitsu Hamasaki

  238. Box and Cox power-transformation to confined and censored nonnormal responses in regression

    Article • Computational Statistics & Data Analysis, May 2007, Elsevier

    Dr Toshimitsu Hamasaki

  239. A COMPARISON OF METHODS FOR PARAMETER ESTIMATION OF THE SHIFTED POWER TRANSFORMATION

    Article • Journal of the Japanese Society of Computational Statistics, January 2007, Japanese Society of Computational Statistics

    Dr Toshimitsu Hamasaki

  240. The Role of Randomization in Clinical Trials

    Article • Ouyou toukeigaku, January 2007, Japanese Society of Applied Statistics

    Dr Toshimitsu Hamasaki

  241. Properties of estimators of baseline hazard functions in a semiparametric cure model

    Article • Annals of the Institute of Statistical Mathematics, September 2006, Springer Science + Business Media

    Dr Toshimitsu Hamasaki

  242. A placebo-controlled, randomized withdrawal study of sertraline for major depressive disorder in Japan

    Article • International Clinical Psychopharmacology, January 2006, Wolters Kluwer Health

    Dr Toshimitsu Hamasaki

  243. A Digital Input Controller for Audio Class-D Amplifiers with 100W 0.004% THD+N and 113dB DR

    Article • January 2006, Institute of Electrical & Electronics Engineers (IEEE)

    Dr Toshimitsu Hamasaki

  244. Vitamin K2 ameliorates experimental autoimmune encephalomyelitis in Lewis rats

    Article • Journal of Neuroimmunology, December 2005, Elsevier

    Dr Toshimitsu Hamasaki

  245. Rapid disease progression correlates with instability of mutant SOD1 in familial ALS

    Article • Neurology, November 2005, Wolters Kluwer Health

    Dr Toshimitsu Hamasaki

  246. A placebo-controlled, randomized withdrawal study of sertraline for panic disorder in Japan

    Article • International Clinical Psychopharmacology, September 2005, Wolters Kluwer Health

    Dr Toshimitsu Hamasaki

  247. POWER-TRANSFORMATION MODEL TO ADDITIVITY IN REGRESSION

    Article • Behaviormetrika, January 2005, Behaviormetric Society of Japan

    Dr Toshimitsu Hamasaki

  248. ASYMPTOTIC PROPERTIES OF ESTIMATES OF THE POWER-TRANSFORMATION MODEL TO BIVARIATE GROUPED DATA

    Article • Journal of the Japanese Society of Computational Statistics, January 2005, Japanese Society of Computational Statistics

    Dr Toshimitsu Hamasaki

  249. ESTIMATION FROM PSEUDO PARTIAL LIKELIHOOD IN A SEMIPARAMETRIC CURE MODEL

    Article • Journal of the Japanese Society of Computational Statistics, January 2005, Japanese Society of Computational Statistics

    Dr Toshimitsu Hamasaki

  250. Benefit of valproic acid in suppressing disease progression of ALS model mice

    Article • European Journal of Neuroscience, December 2004, Wiley

    Dr Toshimitsu Hamasaki

  251. 2. Clinical and Medical Evaluation Process

    Article • Journal of the Japanese Society of Computational Statistics, January 2003, Japanese Society of Computational Statistics

    Dr Toshimitsu Hamasaki

  252. SIMULTANEOUS DIAGNOSTIC METHODS FOR THE DOUBLE POWER-NORMAL TRANSFORMATION MODEL

    Article • Journal of the Japanese Society of Computational Statistics, January 2003, Japanese Society of Computational Statistics

    Dr Toshimitsu Hamasaki

  253. PRACTICAL ISSUES AND OBSERVATIONS ON THE USE OF FOREIGN CLINICAL DATA IN DRUG DEVELOPMENT

    Article • Journal of Biopharmaceutical Statistics, January 2002, Taylor & Francis

    Dr Toshimitsu Hamasaki

  254. STATISTICAL INFERENCES OF GROUPED DATA COMBINED WITH UNGROUPED DATA FROM THE POWER-NORMAL DISTRIBUTION

    Article • Journal of the Japanese Society of Computational Statistics, January 2002, Japanese Society of Computational Statistics

    Dr Toshimitsu Hamasaki

  255. On Inferences of Parameters in the Bivariate Power-Normal Distribution

    Article • Kodo Keiryogaku (The Japanese Journal of Behaviormetrics), January 2002, Behaviormetric Society of Japan

    Dr Toshimitsu Hamasaki

  256. Statistical Approaches to Detecting Dose-Response Relationships

    Article • Drug Information Journal, April 2000, Springer Science + Business Media

    Dr Toshimitsu Hamasaki

  257. Article • Ouyou toukeigaku, January 1999, Japanese Society of Applied Statistics

    Dr Toshimitsu Hamasaki

  258. INFERENCES BASED ON THE GROUPED OBSERVATIONS FROM THE BIVARIATE POWER-NORMAL DISTRIBUTION

    Article • Journal of the Japanese Society of Computational Statistics, January 1998, Japanese Society of Computational Statistics

    Dr Toshimitsu Hamasaki

  259. Fitting power normal distribution to grouped observations

    Article • Kodo Keiryogaku (The Japanese Journal of Behaviormetrics), January 1998, Behaviormetric Society of Japan

    Dr Toshimitsu Hamasaki

  260. Article • Ouyou toukeigaku, January 1998, Japanese Society of Applied Statistics

    Dr Toshimitsu Hamasaki

  261. Autostereoscopic 3‐D television experiments

    Article • January 1980, American Institute of Physics

    Dr Toshimitsu Hamasaki

  262. Launch, Tracking and Control

    Article • The Journal of the Institute of Television Engineers of Japan, January 1979, Institute of Image Information and Television Engineers

    Dr Toshimitsu Hamasaki